84 results
Page 4 of 5
S-3
EX-1.1
viu76p8d
20 Dec 19
Shelf registration
4:17pm
8-K
EX-99.1
dki7wif
12 Nov 19
UroGen Pharma Reports Third Quarter 2019 Financial Results and Recent
8:06am
8-K
EX-99.1
o6kxz3j4xri235oeb
24 Sep 19
Durability of Response Determined to be 89 Percent at Six Months and 84 Percent at 12 Months
5:20pm
8-K
EX-99.2
ogr1iz
24 Sep 19
Durability of Response Determined to be 89 Percent at Six Months and 84 Percent at 12 Months
5:20pm
8-K
EX-99.1
lv41 iv7v
9 Aug 19
UroGen Pharma Reports Second Quarter 2019 Financial Results and Recent
8:16am
8-K
EX-99.1
8n8ahdqyfxfq ui
9 May 19
UroGen Pharma Reports First Quarter 2019 Financial Results and Recent
8:12am
10-Q
alcib1
9 May 19
Quarterly report
7:13am
DEF 14A
woxeli3y
26 Apr 19
Definitive proxy
5:00pm
10-K
f0sr3b
28 Feb 19
Annual report
1:08pm
10-K
EX-10.11
t11ivc
28 Feb 19
Annual report
1:08pm
10-K
EX-10.10
oufn 37oknkq6
28 Feb 19
Annual report
1:08pm
10-K
EX-10.9
wqz4 5t6g
28 Feb 19
Annual report
1:08pm
10-K
EX-10.12
prfou
28 Feb 19
Annual report
1:08pm
424B5
y2cd fugon4ywozipbk
25 Jan 19
Prospectus supplement for primary offering
8:01am
8-K
EX-1.1
9lo0f wvczea
25 Jan 19
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares
7:30am
424B5
z8tt7y nt0t3jxc
22 Jan 19
Prospectus supplement for primary offering
5:12pm
8-K
EX-99.2
jbt3ifb
22 Jan 19
UroGen Pharma Announces Proposed Public Offering of Ordinary Shares
5:08pm
6-K
EX-99.1
h9vpuox0a62sxy
31 Oct 18
UGN-101 Joins Select Group of Urologic Oncology Product Candidates to Receive BTD
3:36pm